Chemical Nameidarucizumab
Dosage FormInjection (intravenous; 2.5 g/50 mL)
Drug ClassHumanized monoclonal antibody fragment (Fab)
CompanyBoehringer Ingelheim
Approval Year2015


  • Indicated in patients treated with Pradaxa┬« when reversal of the anticoagulant effects of dabigatran is needed for emergency surgery/urgent procedures or in life-threatening or uncontrolled bleeding.
Document TitleYearSource
Praxbind (idarucizumab) Prescribing Information.2021Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT
Drug updated on 6/5/2023

More on this drug: Clinical Trials